Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

August 20, 2007 09:00 ET

Urodynamix and Laborie to Exhibit at ICS 2007

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 20, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that the prototype URO-NIRS Bladder Monitor system will be on display to an international audience of physicians, surgeons and nurses attending the 37th Annual Meeting of the International Continence Society ("ICS") in Rotterdam, Netherlands from August 20-24, 2007.

Urodynamix and Laborie Medical Technologies ("Laborie") will exhibit a working prototype of the URO-NIRS Bladder Monitor system that is fully integrated with Laborie's Urodynamics System. The demonstrations will be held during the ICS technical exhibition at the Concert and Congres Centre de Doelen (Laborie Booth 1.35). The URO-NIRS Bladder Monitor system is an investigational device and is not currently available for sale.

Urodynamix is developing the integrated URO-NIRS Bladder Monitor for non-invasive urodynamics testing to aid in the diagnosis of patients with lower urinary tract symptoms. In May 2007, Urodynamix entered into a worldwide licensing agreement with Laborie to distribute URO-NIRS technology in acute care settings (see news release dated May 17, 2007 for details).

Subject to regulatory approvals and Laborie's launch program, Urodynamix expects the URO-NIRS Bladder Monitor system to be available for launch in the US, Europe and Canada by the end of 2007.

About ICS 2007

The International Continence Society was founded in 1971 and boasts a membership of well over 1,800 from 64 different countries. The primary interest of the ICS is to study storage and voiding function of the lower urinary tract, its diagnosis and the management of lower urinary tract dysfunction, and to encourage research into pathophysiology, diagnostic techniques and treatment. It meets annually with a different meeting chair and venue each year and remains one of the most valued dates in the urological calendar, attracting in excess of 3,000 delegates from all corners of the globe.

About Laborie Medical Technologies

Founded in 1967 by Ray Laborie, a Canadian medical device specialist, Laborie Medical Technologies is the leading global manufacturer of urodynamics equipment used in the diagnosis and treatment of incontinence. Laborie's product line consists of the industry's most advanced urodynamics, compact ultrasound imaging and biofeedback/stimulation systems, patient management software, catheters and disposables. In addition to utilizing the latest advances in technology, Laborie produces and sponsors leading educational courses in urodynamics for doctors, nurses and technicians around the world each year.

Laborie introduced the first computerized Urodynamics UDS™ processor in 1984, and now claims the largest and most knowledgeable UDS sales force in the world with offices in Ontario, Quebec, Vermont, Belgium, China and now the UK. It has direct sales and distribution networks in 52 countries across North America, Europe and Austral-Asia. In addition to an extensive sales force, Laborie's team of over 30 on-staff engineers, field technicians and UDS nurses install UDS systems, train users, and work in concert with leading clinician-researchers and local universities. These resources ensure that Laborie can bring the talent and technical knowledge necessary to assure that its products incorporate the most recent advancements and also reflect the practical realities of the typical urology or urogynecology clinic.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for large and growing global healthcare markets. The Company is currently developing medical devices that use near-infrared spectroscopy (NIRS) to aid in the diagnosis and treatment of urological conditions, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. Urodynamix's disruptive technology has the potential to beneficially affect more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information